NZ560696A - Use of erythropoietin based medicaments for the protection of a mammal from pathology resulting from injury to excitable tissue - Google Patents
Use of erythropoietin based medicaments for the protection of a mammal from pathology resulting from injury to excitable tissueInfo
- Publication number
- NZ560696A NZ560696A NZ560696A NZ56069600A NZ560696A NZ 560696 A NZ560696 A NZ 560696A NZ 560696 A NZ560696 A NZ 560696A NZ 56069600 A NZ56069600 A NZ 56069600A NZ 560696 A NZ560696 A NZ 560696A
- Authority
- NZ
- New Zealand
- Prior art keywords
- epo
- injury
- mammal
- excitable tissue
- protection
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title abstract 9
- 108090000394 Erythropoietin Proteins 0.000 title abstract 9
- 229940105423 erythropoietin Drugs 0.000 title abstract 9
- 208000014674 injury Diseases 0.000 title abstract 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 6
- 208000027418 Wounds and injury Diseases 0.000 title abstract 5
- 230000006378 damage Effects 0.000 title abstract 5
- 241000124008 Mammalia Species 0.000 title abstract 2
- 230000007170 pathology Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 102000005962 receptors Human genes 0.000 abstract 3
- 108020003175 receptors Proteins 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 229940075993 receptor modulator Drugs 0.000 abstract 2
- 230000002207 retinal effect Effects 0.000 abstract 2
- 206010003591 Ataxia Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 208000032253 retinal ischemia Diseases 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29093899A | 1999-04-13 | 1999-04-13 | |
| US54722000A | 2000-04-11 | 2000-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ560696A true NZ560696A (en) | 2010-03-26 |
Family
ID=26966493
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ533098A NZ533098A (en) | 1999-04-13 | 2000-04-13 | Modulation of excitable tissue function by peripherally administered erythropoietin at high doses |
| NZ545478A NZ545478A (en) | 1999-04-13 | 2000-04-13 | Modulation of excitable tissue function by peripherally administered erythropoietin |
| NZ560696A NZ560696A (en) | 1999-04-13 | 2000-04-13 | Use of erythropoietin based medicaments for the protection of a mammal from pathology resulting from injury to excitable tissue |
| NZ514690A NZ514690A (en) | 1999-04-13 | 2000-04-13 | Modulation of excitable tissue function by peripherally administered erythropoietin |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ533098A NZ533098A (en) | 1999-04-13 | 2000-04-13 | Modulation of excitable tissue function by peripherally administered erythropoietin at high doses |
| NZ545478A NZ545478A (en) | 1999-04-13 | 2000-04-13 | Modulation of excitable tissue function by peripherally administered erythropoietin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ514690A NZ514690A (en) | 1999-04-13 | 2000-04-13 | Modulation of excitable tissue function by peripherally administered erythropoietin |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1171147A4 (xx) |
| JP (1) | JP2003520194A (xx) |
| KR (2) | KR100883232B1 (xx) |
| CN (1) | CN1607957B (xx) |
| AU (1) | AU784550B2 (xx) |
| BG (1) | BG65353B1 (xx) |
| BR (1) | BR0009737A (xx) |
| CA (1) | CA2383940A1 (xx) |
| CR (1) | CR6501A (xx) |
| CZ (1) | CZ20013695A3 (xx) |
| EA (1) | EA004766B1 (xx) |
| HU (1) | HUP0201598A3 (xx) |
| IL (2) | IL145895A0 (xx) |
| IS (1) | IS6104A (xx) |
| MX (1) | MXPA01010177A (xx) |
| NO (1) | NO20014991L (xx) |
| NZ (4) | NZ533098A (xx) |
| PL (1) | PL352223A1 (xx) |
| SK (1) | SK14412001A3 (xx) |
| TR (2) | TR200402194T2 (xx) |
| WO (1) | WO2000061164A1 (xx) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
| US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| EP1295604B1 (en) * | 2000-06-30 | 2009-09-30 | Tokyo Metropolitan Institute of Gerontology | Preventives and remedies for diseases in association with demyelination |
| DE10043457A1 (de) * | 2000-09-04 | 2002-03-28 | Hannelore Ehrenreich | Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| KR100896971B1 (ko) * | 2001-02-02 | 2009-05-14 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 프락토피라노오스 설파메이트 및 에리트로포이에틴을포함하는 신경계 기능장애 치료법 |
| US20030118630A1 (en) * | 2001-12-07 | 2003-06-26 | Anthony Cerami | Immune modulation device for use in animals |
| ATE542904T1 (de) | 2001-10-29 | 2012-02-15 | Crucell Holland Bv | Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen |
| KR100979025B1 (ko) | 2001-12-07 | 2010-08-30 | 크루셀 홀란드 비.브이. | 바이러스, 바이러스 단리물 및 백신의 생산 |
| ATE359087T1 (de) * | 2002-01-09 | 2007-05-15 | Crucell Holland Bv | Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen |
| AU2002307635A1 (en) * | 2002-04-19 | 2003-11-03 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
| GB0211578D0 (en) | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
| CA2491567A1 (en) * | 2002-07-01 | 2004-01-08 | The Kenneth S. Warren Institute, Inc. | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
| JP2006521405A (ja) * | 2003-03-27 | 2006-09-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 発作回復におけるエリトロポイエチンの使用 |
| US7718363B2 (en) * | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| ATE414144T1 (de) | 2003-05-09 | 2008-11-15 | Crucell Holland Bv | Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon |
| DE102004004509B4 (de) * | 2004-01-23 | 2010-07-01 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
| AT500929B1 (de) | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
| PT2371855E (pt) | 2005-08-05 | 2015-11-03 | Araim Pharmaceuticals Inc | Péptidos protetores de tecidos e suas utilizações |
| US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
| GB0525540D0 (en) * | 2005-12-15 | 2006-01-25 | Isis Innovation | New treatment |
| DE102006004008A1 (de) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose |
| CN101062407A (zh) * | 2006-04-29 | 2007-10-31 | 中国科学院上海生命科学研究院 | 促红细胞生成素在预防或治疗视网膜损伤中的用途 |
| US8133860B2 (en) * | 2006-07-20 | 2012-03-13 | Rosalind Franklin University Of Medicine And Science | Facilitation of resuscitation from cardiac arrest by erythropoietin |
| JP2010515736A (ja) * | 2007-01-10 | 2010-05-13 | エジソン ファーマシューティカルズ， インコーポレイテッド | エリスロポイエチン活性またはトロンボポイエチン活性を有する化合物を用いる呼吸鎖障害の治療 |
| WO2009010107A1 (en) * | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
| SG10201604530SA (en) | 2008-01-22 | 2016-07-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| RU2385746C1 (ru) * | 2008-07-18 | 2010-04-10 | Владимир Алексеевич Шатров | Способ лечения детского церебрального паралича |
| RU2432899C1 (ru) * | 2010-03-23 | 2011-11-10 | Владимир Алексеевич Тупиков | Способ прогнозирования рецидива эквинусной и эквиноварусной деформаций стопы после их раннего хирургического лечения у детей с дцп |
| RU2519695C2 (ru) * | 2010-07-21 | 2014-06-20 | Олег Ильич Эпштейн | Лекарственное средство для лечения синдрома дефицита внимания и способ лечения синдрома дефицита внимания |
| CN111066727B (zh) * | 2019-12-20 | 2021-08-27 | 中国人民解放军陆军军医大学 | 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
| US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| US5661125A (en) * | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| DE19857609A1 (de) * | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
-
2000
- 2000-04-13 PL PL00352223A patent/PL352223A1/xx not_active Application Discontinuation
- 2000-04-13 NZ NZ533098A patent/NZ533098A/en not_active IP Right Cessation
- 2000-04-13 SK SK1441-2001A patent/SK14412001A3/sk not_active Application Discontinuation
- 2000-04-13 NZ NZ545478A patent/NZ545478A/en not_active IP Right Cessation
- 2000-04-13 EA EA200101073A patent/EA004766B1/ru not_active IP Right Cessation
- 2000-04-13 CN CN008087466A patent/CN1607957B/zh not_active Expired - Lifetime
- 2000-04-13 CZ CZ20013695A patent/CZ20013695A3/cs unknown
- 2000-04-13 NZ NZ560696A patent/NZ560696A/xx not_active IP Right Cessation
- 2000-04-13 EP EP00923344A patent/EP1171147A4/en not_active Ceased
- 2000-04-13 TR TR2004/02194T patent/TR200402194T2/xx unknown
- 2000-04-13 HU HU0201598A patent/HUP0201598A3/hu unknown
- 2000-04-13 WO PCT/US2000/010019 patent/WO2000061164A1/en not_active Ceased
- 2000-04-13 KR KR1020017013093A patent/KR100883232B1/ko not_active Expired - Fee Related
- 2000-04-13 AU AU43487/00A patent/AU784550B2/en not_active Expired
- 2000-04-13 IL IL14589500A patent/IL145895A0/xx unknown
- 2000-04-13 JP JP2000610496A patent/JP2003520194A/ja active Pending
- 2000-04-13 CA CA002383940A patent/CA2383940A1/en not_active Abandoned
- 2000-04-13 TR TR2001/03785T patent/TR200103785T2/xx unknown
- 2000-04-13 MX MXPA01010177A patent/MXPA01010177A/es active IP Right Grant
- 2000-04-13 NZ NZ514690A patent/NZ514690A/en not_active IP Right Cessation
- 2000-04-13 BR BR0009737-3A patent/BR0009737A/pt not_active Application Discontinuation
- 2000-04-13 KR KR1020077021154A patent/KR101012932B1/ko not_active Expired - Fee Related
-
2001
- 2001-10-11 IS IS6104A patent/IS6104A/is unknown
- 2001-10-11 IL IL145895A patent/IL145895A/en not_active IP Right Cessation
- 2001-10-12 NO NO20014991A patent/NO20014991L/no not_active Application Discontinuation
- 2001-10-26 BG BG106058A patent/BG65353B1/bg unknown
- 2001-11-13 CR CR6501A patent/CR6501A/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ560696A (en) | Use of erythropoietin based medicaments for the protection of a mammal from pathology resulting from injury to excitable tissue | |
| IL126132A0 (en) | Improved antiperspirant stick composition | |
| MY131810A (en) | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | |
| EP0998925A4 (en) | TOPICAL ADMINISTRATION COMPOSITIONS CONTAINING VITAMINS D AND VITAMINS K | |
| CA2054822A1 (en) | Formulations and their use in the treatment of neurological diseases | |
| HUT71889A (en) | Pharmaceutical compositions containing terfenadine metabolites and their optically pure isomers for treating allergic disorders | |
| CA2302396A1 (en) | Allosteric adenosine receptor modulators | |
| HUT68498A (en) | L-dopa ester compositions and process to prepare them | |
| CA2282427A1 (en) | Controlled release of pharmaceuticals in the anterior chamber of the eye | |
| MX9603489A (es) | Peptidos opiodes novedosos para el tratamiento del dolor y uso de los mismos. | |
| EP1671973A3 (en) | Allosteric adenosine receptor modulators | |
| CA2143610A1 (en) | Use of norastemizole for the treatment of allergic disorders | |
| HUP0100024A3 (en) | Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient | |
| MY124465A (en) | Reduction of infarct volume using citicoline | |
| EP0393707A3 (en) | Bioactive compounds associated with liposomes and their use in pharmaceutical preparations | |
| ZA95150B (en) | Application of riluzole in the treatment of mitochondrial diseases | |
| TR200103144T2 (tr) | Yeni bileşikler | |
| CA2091134A1 (en) | Therapeutic agent for threatened abortion | |
| RU92006715A (ru) | Местноанестезирующее средство для глаз | |
| GR3034062T3 (en) | Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease | |
| MXPA04002099A (es) | Composiciones medicinales para neuropatia diabetica. | |
| WO2000056336A3 (en) | Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin | |
| PL292558A1 (en) | Cosmetic agent for treating damages caused by heat and light radiation | |
| CA2137755A1 (en) | Palliation of sickle cell disorders by phenylurea, benzylurea, or phenylethylurea or by a homolog ring-substituted with one methoxyl, methyl, or hydroxyl radical | |
| CN2079949U (zh) | 药物护膝 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 13 APR 2020 BY CPA GLOBAL Effective date: 20130308 |
|
| EXPY | Patent expired |